Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir Prophylaxis for HBV Reactivation in HCV/HBV Co-infected Patients on DAA Therapy
NCT04405011Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of entecavir in hepatitis B (HBV) (3 arms), sponsored by National Taiwan University Hospital. Primary endpoint: HBV virologic and clinical reactivation rates at 72 weeks. Status: unknown.
02
Drugs
entecavir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04405011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405011.